Innovate UK, LifeArc, and Medicines Discovery Catapult believe that the best approach to addressing AMR and protecting the lives of people around the world is to grow a pipeline of high-quality antimicrobial drugs and associated diagnostics. So we came together to set up PACE to combine our expertise and resources, knowing that we can make a bigger impact together than we could alone.
LifeArc is a self-funded, not-for-profit medical research organisation, focused on translational science. We carry out our own research and provide funding and expert advice to others, all with the aim of improving patient lives.
One of our areas of focus is global health, where we are collaborating to accelerate innovation in infectious diseases. This includes our translational challenge in AMR, which aims to drive the better use of existing treatments and the development of new targeted therapies and diagnostics for AMR. PACE will be a vital part of this work.
LifeArc is registered charity in England and Wales under no. 1015243 and in Scotland under no. SC037861.
Innovate UK, the national innovation agency, drives transformational change in health innovation to enable people to live longer healthy lives, and realise the UK’s position as a world-leader in life sciences.
We empower early-stage, high-growth potential businesses from across the UK by granting them access to partners, facilities, funding, and valuable advice. This support will enable these businesses to grow and effectively confront the significant challenge that AMR poses.
Innovate UK will play a leading role in building an innovation ecosystem around AMR that accelerates new discoveries and promotes economic growth for UK businesses.
Medicines Discovery Catapult (MDC)
Medicines Discovery Catapult reshapes drug discovery for patient benefit by transforming great UK science into better treatments through partnership. Through PACE, we will bring the AMR community together, and make it easier for innovators to turn their ideas into novel therapeutics and diagnostics. We offer our world-class capabilities so, together, we can accelerate the pace of antimicrobial innovation and save lives.
Across our three Managing Partners, we have selected the very best people to run PACE. We have created a team that has deep expertise in AMR and far-reaching connections across the health sector.
Dr. Bev Isherwood
PACE Programme Director
As PACE Programme Director, Dr. Bev Isherwood will oversee strategic direction, deployment and operational translation of PACE.
Dr. Clive Mason
PACE Programme Director
As PACE Programme Director, Dr. Clive Mason will oversee strategic direction of PACE and establish strong scientific engagement with the AMR community.
Dr. Pete Coombs
As a PACE Scientific Lead, Dr. Pete Coombs will support and manage the PACE project portfolio, collaborative delivery partner network and collaborative R&D portfolio.
Dr. Neill Gingles
As a PACE Scientific Lead, Dr. Neill Gingles will support and manage the PACE project portfolio, collaborative delivery partner network and collaborative R&D portfolio.
Dr. Tanja Taylor
As a PACE Scientific Lead, Dr. Tanja Taylor will oversee pipeline development and diligence of the PACE project portfolio of ventures and collaborative R&D projects.
Dr. Elena Breidenstein
As a PACE R&D Advisor, Dr. Elena Breidenstein will work closely with PACE funded project teams to help them access the right support at the right time.
Experts in AMR, innovation and early-stage translation will be closely involved in the governance and management of the PACE fund to make sure funds are awarded in a way that is most effective for the industry and most fair and inclusive for applicants and delivery partners.
Working with us
If you are an innovator in AMR, then we can increase the pace of your research and make sure it has the best chance of succeeding. PACE will bring together the right funding, resources, and partnerships to help progress early-stage antimicrobial drug and diagnostics projects that address the world’s most threatening pathogens. Learn more about how we can help you.Apply for Funding
Dr Ron Daniels BEM
Founder and Joint CEO, UK Sepsis Trust